Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials.
Journal
Nutrition & diabetes
ISSN: 2044-4052
Titre abrégé: Nutr Diabetes
Pays: England
ID NLM: 101566341
Informations de publication
Date de publication:
16 May 2024
16 May 2024
Historique:
received:
26
12
2023
accepted:
01
05
2024
revised:
26
04
2024
medline:
17
5
2024
pubmed:
17
5
2024
entrez:
16
5
2024
Statut:
epublish
Résumé
Metabolic syndrome (MetS) is a cluster of interconnected risk factors that significantly increase the likelihood of cardiovascular disease and type 2 diabetes. Taurine has emerged as a potential therapeutic agent for MetS. This meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the effects of taurine supplementation on MetS-related parameters. We conducted electronic searches through databases like Embase, PubMed, Web of Science, Cochrane CENTRAL, and ClinicalTrials.gov, encompassing publications up to December 1, 2023. Our analysis focused on established MetS diagnostic criteria, including systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C). Meta-regression explored potential dose-dependent relationships based on the total taurine dose administered during the treatment period. We also assessed secondary outcomes like body composition, lipid profile, and glycemic control. Our analysis included 1024 participants from 25 RCTs. The daily dosage of taurine in the studies ranged from 0.5 g/day to 6 g/day, with follow-up periods varying between 5 and 365 days. Compared to control groups, taurine supplementation demonstrated statistically significant reductions in SBP (weighted mean difference [WMD] = -3.999 mmHg, 95% confidence interval [CI] = -7.293 to -0.706, p = 0.017), DBP (WMD = -1.509 mmHg, 95% CI = -2.479 to -0.539, p = 0.002), FBG (WMD: -5.882 mg/dL, 95% CI: -10.747 to -1.018, p = 0.018), TG (WMD: -18.315 mg/dL, 95% CI: -25.628 to -11.002, p < 0.001), but not in HDL-C (WMD: 0.644 mg/dl, 95% CI: -0.244 to 1.532, p = 0.155). Meta-regression analysis revealed a dose-dependent reduction in DBP (coefficient = -0.0108 mmHg per g, p = 0.0297) and FBG (coefficient = -0.0445 mg/dL per g, p = 0.0273). No significant adverse effects were observed compared to the control group. Taurine supplementation exhibits positive effects on multiple MetS-related factors, making it a potential dietary addition for individuals at risk of or already experiencing MetS. Future research may explore dose-optimization strategies and potential long-term benefits of taurine for MetS management.
Sections du résumé
BACKGROUND
BACKGROUND
Metabolic syndrome (MetS) is a cluster of interconnected risk factors that significantly increase the likelihood of cardiovascular disease and type 2 diabetes. Taurine has emerged as a potential therapeutic agent for MetS. This meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the effects of taurine supplementation on MetS-related parameters.
METHODS
METHODS
We conducted electronic searches through databases like Embase, PubMed, Web of Science, Cochrane CENTRAL, and ClinicalTrials.gov, encompassing publications up to December 1, 2023. Our analysis focused on established MetS diagnostic criteria, including systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C). Meta-regression explored potential dose-dependent relationships based on the total taurine dose administered during the treatment period. We also assessed secondary outcomes like body composition, lipid profile, and glycemic control.
RESULTS
RESULTS
Our analysis included 1024 participants from 25 RCTs. The daily dosage of taurine in the studies ranged from 0.5 g/day to 6 g/day, with follow-up periods varying between 5 and 365 days. Compared to control groups, taurine supplementation demonstrated statistically significant reductions in SBP (weighted mean difference [WMD] = -3.999 mmHg, 95% confidence interval [CI] = -7.293 to -0.706, p = 0.017), DBP (WMD = -1.509 mmHg, 95% CI = -2.479 to -0.539, p = 0.002), FBG (WMD: -5.882 mg/dL, 95% CI: -10.747 to -1.018, p = 0.018), TG (WMD: -18.315 mg/dL, 95% CI: -25.628 to -11.002, p < 0.001), but not in HDL-C (WMD: 0.644 mg/dl, 95% CI: -0.244 to 1.532, p = 0.155). Meta-regression analysis revealed a dose-dependent reduction in DBP (coefficient = -0.0108 mmHg per g, p = 0.0297) and FBG (coefficient = -0.0445 mg/dL per g, p = 0.0273). No significant adverse effects were observed compared to the control group.
CONCLUSION
CONCLUSIONS
Taurine supplementation exhibits positive effects on multiple MetS-related factors, making it a potential dietary addition for individuals at risk of or already experiencing MetS. Future research may explore dose-optimization strategies and potential long-term benefits of taurine for MetS management.
Identifiants
pubmed: 38755142
doi: 10.1038/s41387-024-00289-z
pii: 10.1038/s41387-024-00289-z
doi:
Types de publication
Systematic Review
Meta-Analysis
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
29Subventions
Organisme : Ministry of Science and Technology, Taiwan (Ministry of Science and Technology of Taiwan)
ID : MOST 106-2314-B-002-180-MY3 and MOST 109-2314-B-002-114-MY3
Informations de copyright
© 2024. The Author(s).
Références
Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018;20:12.
pubmed: 29480368
pmcid: 5866840
doi: 10.1007/s11906-018-0812-z
Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–8.
pubmed: 14744958
doi: 10.1161/01.CIR.0000111245.75752.C6
Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112:3066–72.
pubmed: 16275870
doi: 10.1161/CIRCULATIONAHA.105.539528
Wright CE, Tallan HH, Lin YY, Gaull GE. Taurine: biological update. Annu Rev Biochem. 1986;55:427–53.
pubmed: 3527049
doi: 10.1146/annurev.bi.55.070186.002235
Tao X, Zhang Z, Yang Z, Rao B. The effects of taurine supplementation on diabetes mellitus in humans: a systematic review and meta-analysis.Food Chem.2022;4:100–106.
Qaradakhi T, Gadanec LK, McSweeney KR, Abraham JR, Apostolopoulos V, Zulli A. The anti-inflammatory effect of taurine on cardiovascular disease. Nutrients. 2020;12:2847.
pubmed: 32957558
pmcid: 7551180
doi: 10.3390/nu12092847
Spohr C, Brøns C, Winther K, Dyerberg J, Vaag A. No effect of taurine on platelet aggregation in men with a predisposition to type 2 diabetes mellitus. Platelets. 2005;16:301–5.
pubmed: 16011981
doi: 10.1080/09537100400020575
Zhang M, Bi LF, Fang JH, Su XL, Da GL, Kuwamori T, et al. Beneficial effects of taurine on serum lipids in overweight or obese non-diabetic subjects. Amino Acids. 2004;26:267–71.
pubmed: 15221507
doi: 10.1007/s00726-003-0059-z
Page MJ, Higgins JPT, Sterne JAC. Assessing risk of bias due to missing results in a synthesis. In Cochrane handbook for systematic re views of interventions. 2021;2023:Version 6.2 edn UK: Cochrane Training.
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
pubmed: 31462531
doi: 10.1136/bmj.l4898
Deeks JJ, Higgins JPT, Altman DG. Analysing data and undertaking meta-analyses. In Cochrane handbook forsystematic reviews of interventions. Version 6.2 vol. 2023, 2021 UK: Cochrane Training.
Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.
pubmed: 15840177
pmcid: 1097734
doi: 10.1186/1471-2288-5-13
Higgins JPT, Li T, Deeks JJ. Choosing effect measures and computing estimates of effect. Cochrane handbook for systematic reviews of interventions. 2021;2023: Version 6.2. UK: Cochrane Training.
Higgins JPT, Li T, Deeks, AJ. Choosing effect measures and computing estimates of effect. Cochrane handbook for systematic reviews of interventions, vol. 2023, 2021.
Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1:97–111.
pubmed: 26061376
doi: 10.1002/jrsm.12
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
pubmed: 12958120
pmcid: 192859
doi: 10.1136/bmj.327.7414.557
Ahmadian M, Roshan VD, Aslani E, Stannard SR. Taurine supplementation has anti-atherogenic and anti-inflammatory effects before and after incremental exercise in heart failure. Ther Adv Cardiovasc Dis. 2017;11:185–94.
pubmed: 28580833
pmcid: 5933646
doi: 10.1177/1753944717711138
Ahmadian M, Dabidi Roshan V, Ashourpore E. Taurine supplementation improves functional capacity, myocardial oxygen consumption, and electrical activity in heart failure. Journal of dietary supplements. 2017;14:422–32.
pubmed: 28118062
doi: 10.1080/19390211.2016.1267059
Arrieta F, Balsa JA, de la Puerta C, Botella JI, Zamarron I, Elias E, et al. Phase IV prospective clinical study to evaluate the effect of taurine on liver function in postsurgical adult patients requiring parenteral nutrition. Nutr Clin Pract. 2014;29:672–80.
pubmed: 24829298
doi: 10.1177/0884533614533610
Averin E. Use of taurine during rehabilitation after cardiac surgery. Adv Exp Med Biol. 2015;803:637–49.
pubmed: 25833533
doi: 10.1007/978-3-319-15126-7_51
Azuma J, Sawamura A, Awata N, Ohta H, Hamaguchi T, Harada H, et al. Therapeutic effect of taurine in congestive heart failure: a double-blind crossover trial. Clin Cardiol. 1985;8:276–82.
pubmed: 3888464
doi: 10.1002/clc.4960080507
Azuma J, Sawamura A, Awata N. Double-blind randomized crossover trial of taurine in congestive heart failure. Curr Ther Res Clin Exp. 1983;34:543–57.
Azuma J, Sawamura A, Awata N. Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ J. 1992;56:95–99.
pubmed: 1538580
doi: 10.1253/jcj.56.95
Batitucci G, Brandao CFC, De Carvalho FG, Marchini JS, Pfrimer K, Ferrioli E, et al. Taurine supplementation increases irisin levels after high intensity physical training in obese women. Cytokine. 2019;123:154741.
pubmed: 31226435
doi: 10.1016/j.cyto.2019.154741
Beyranvand MR, Khalafi MK, Roshan VD, Choobineh S, Parsa SA, Piranfar MA. Effect of taurine supplementation on exercise capacity of patients with heart failure. J Cardiol. 2011;57:333–7.
pubmed: 21334852
doi: 10.1016/j.jjcc.2011.01.007
Esmaeili F, Maleki V, Kheirouri S, Alizadeh M. The effects of taurine supplementation on metabolic profiles, pentosidine, soluble receptor of advanced glycation end products and methylglyoxal in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Can J Diabetes. 2021;45:39–46.
pubmed: 32861603
doi: 10.1016/j.jcjd.2020.05.004
Fujita T, Ando K, Noda H, Ito Y, Sato Y. Effects of increased adrenomedullary activity and taurine in young-patients with borderline hypertension. Circulation. 1987;75:525–32.
pubmed: 3815764
doi: 10.1161/01.CIR.75.3.525
Hsieh Y-L, Yeh Y-H, Lee Y-T, Huang C-Y. Effect of taurine in chronic alcoholic patients. Food Funct. 2014;5:1529–35. https://doi.org/10.1039/C3FO60597C
doi: 10.1039/C3FO60597C
pubmed: 24841875
Maleki V, Alizadeh M, Esmaeili F, Mahdavi R. The effects of taurine supplementation on glycemic control and serum lipid profile in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Amino Acids. 2020;52:905–14.
pubmed: 32472292
doi: 10.1007/s00726-020-02859-8
Mizushima S, Nara Y, Sawamura M, Yamori Y. Effects of oral taurine supplementation on lipids and sympathetic nerve tone. Adv Exp Med Biol. 1996;403:615–22.
pubmed: 8915402
doi: 10.1007/978-1-4899-0182-8_68
Moloney MA, Casey RG, O’Donnell DH, Fitzgerald P, Thompson C, Bouchier-Hayes DJ. Two weeks taurine supplementation reverses endothelial dysfunction in young male type 1 diabetics. Diabetes Vasc Dis Res. 2010;7:300–10.
doi: 10.1177/1479164110375971
Moludi J, Qaisar SA, Kadhim MM, Ahmadi Y, Davari M. Protective and therapeutic effectiveness of taurine supplementation plus low calorie diet on metabolic parameters and endothelial markers in patients with diabetes mellitus: a randomized, clinical trial. Nutr Metab. 2022;19:49.
doi: 10.1186/s12986-022-00684-2
Ra SG, Choi Y, Akazawa N, Ohmori H, Maeda S. Taurine supplementation attenuates delayed increase in exercise-induced arterial stiffness. Appl Physiol Nutr Metab. 2016;41:618–23.
pubmed: 27163699
doi: 10.1139/apnm-2015-0560
Rosa FT, Freitas EC, Deminice R, Jordão AA, Marchini JS. Oxidative stress and inflammation in obesity after taurine supplementation: a double-blind, placebo-controlled study. Eur J Nutr. 2014;53:823–30.
pubmed: 24065043
doi: 10.1007/s00394-013-0586-7
Schwarzer R, Kivaranovic D, Mandorfer M, Paternostro R, Wolrab D, Heinisch B, et al. Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension. Aliment Pharmacol Ther. 2018;47:86–94.
pubmed: 29105115
doi: 10.1111/apt.14377
Shari FH, Dawood H, Hassan JK, Aljazeari QA, Najm MAA, Salahuddin A, et al. To study the effect of taurine on the effects of vital bones and regulate the level of glucose in type II diabetes. Int J Res Pharm Sci. 2019;10:2545–2551.
doi: 10.26452/ijrps.v10i3.1508
Sun Q, Wang B, Li Y, Sun F, Li P, Xia W, et al. Taurine supplementation lowers blood pressure and improves vascular function in prehypertension: randomized, double-blind, placebo-controlled study. Hypertension. 2016;67:541–9.
pubmed: 26781281
doi: 10.1161/HYPERTENSIONAHA.115.06624
Van Hove JLK, Freehauf CL, Ficicioglu C, Pena LDM, Moreau KL, Henthorn TK, et al. Biomarkers of oxidative stress, inflammation, and vascular dysfunction in inherited cystathionine -synthase deficient homocystinuria and the impact of taurine treatment in a phase 1/2 human clinical trial. J Inherit Metab Dis. 2019;42:424–37.
pubmed: 30873612
doi: 10.1002/jimd.12085
Zaki HV, Sweed MS, Ali RM, Abdelhafeez MA. Taurine as an adjunct therapy for early left ventricular recovery in peripartum cardiomyopathy. J Obstetr Anaesth Crit Care. 2021;11:9–14.
doi: 10.4103/joacc.JOACC_36_20
Ribeiro RA, Bonfleur ML, Batista TM, Borck PC, Carneiro EM. Regulation of glucose and lipid metabolism by the pancreatic and extra-pancreatic actions of taurine. Amino Acids. 2018;50:1511–24.
pubmed: 30206707
doi: 10.1007/s00726-018-2650-3
Camargo RL, Branco RC, de Rezende LF, Vettorazzi JF, Borck PC, Boschero AC, et al. The effect of taurine supplementation on glucose homeostasis: the role of insulin-degrading enzyme. Adv Exp Med Biol. 2015;803:715–24.
pubmed: 25833539
doi: 10.1007/978-3-319-15126-7_57
Vettorazzi JF, Ribeiro RA, Santos-Silva JC, Borck PC, Batista TM, Nardelli TR, et al. Taurine supplementation increases K(ATP) channel protein content, improving Ca2+ handling and insulin secretion in islets from malnourished mice fed on a high-fat diet. Amino Acids. 2014;46:2123–36.
pubmed: 24866813
doi: 10.1007/s00726-014-1763-6
Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem. 2004;279:12152–62.
pubmed: 14699128
doi: 10.1074/jbc.M311113200
Guan L, Miao P. The effects of taurine supplementation on obesity, blood pressure and lipid profile: a meta-analysis of randomized controlled trials. Eur J Pharmacol. 2020;885:173533.
pubmed: 32871172
doi: 10.1016/j.ejphar.2020.173533
Stephan ZF, Lindsey S, Hayes KC. Taurine enhances low density lipoprotein binding. Internalization and degradation by cultured Hep G2 cells. J Biol Chem. 1987;262:6069–73.
pubmed: 3571247
doi: 10.1016/S0021-9258(18)45538-X
Dong Y, Li X, Liu Y, Gao J, Tao J. The molecular targets of taurine confer anti-hyperlipidemic effects. Life Sciences. 2021;278:119579.
pubmed: 33961852
doi: 10.1016/j.lfs.2021.119579
Chen W, Guo J, Zhang Y, Zhang J. The beneficial effects of taurine in preventing metabolic syndrome. Food Funct. 2016;7:1849–63.
pubmed: 26918249
doi: 10.1039/C5FO01295C
Schonfeld G. Lipoproteins in atherogenesis. Artery. 1979;5:305–29.
pubmed: 262160
Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomark Insights. 2016;11:95–104.
pubmed: 27398023
pmcid: 4933534
doi: 10.4137/BMI.S38440
GRAS Exemption Claim for Taurine for Use in Enhanced Water Beverages GRAS Notice (GRN), vol. 2023, No. 822. edn. U.S. Food & Drug Administration. GRAS Notice Inventory.
Williams LL, Lopez LM, Thorman AD, Quay GP, Stein GH, Mehta JL. Plasma lipid profiles and antihypertensive agents: effects of lisinopril, enalapril, nitrendipine, hydralazine, and hydrochlorothiazide. Drug Intell Clin Pharm. 1988;22:546–50.
pubmed: 2843341
Ames R. Effects of diuretic drugs on the lipid profile. Drugs. 1988;36:33–40.
pubmed: 3063504
doi: 10.2165/00003495-198800362-00007
Andreacchi AT, Griffith LE, Guindon GE, Mayhew A, Bassim C, Pigeyre M, et al. Body mass index, waist circumference, waist-to-hip ratio, and body fat in relation to health care use in the Canadian Longitudinal Study on Aging. Int J Obes. 2021;45:666–76.
doi: 10.1038/s41366-020-00731-z